title: [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques].
abstract: The advent of the targeted cancer therapies administered to patients, according to the results of molecular biology techniques (in particular, in situ hybridization, "polymerase chain reaction" amplification and sequencing), has modified the practice of the surgical pathology laboratories. The necessity to answer to the needs of physicians for optimizing the medical care for patients who develop cancer has led to a policy of national debate, spurred by the National Institute of Cancer (INCa), in order to implement new procedures in the pathology laboratories. Thus, in addition to the structuring of molecular biology platforms and their labeling by INCa, the upstream control of the steps present between resection of tumor samples and molecular analysis has proved to be crucial. Indeed, the quality of this upstream time, called "pre-analytical" phase, determines the reliability of the molecular biology results and therefore the therapeutic strategy. We describe here the main steps to be checked in the pre-analytical phase. The optimization of this pre-analytical phase within the surgical pathology laboratory aims to reduce or render insignificant the risk of errors of molecular biology tests. These errors can indeed lead to false negative or false positive results whose therapeutic consequences can be particularly harmful to patients with cancer.
authors.affiliation: Laboratoire de pathologie clinique et expérimentale, hôpital Pasteur, CHU de Nice, 30, avenue de Voie-Romaine, BP 69, 06002 Nice cedex, France. hofman.p@chu-nice.fr
authors.forename: Véronique
authors.initials: V
authors.lastname: Hofman
authors.forename: Marius
authors.initials: M
authors.lastname: Ilie
authors.forename: Virginie
authors.initials: V
authors.lastname: Gavric-Tanga
authors.forename: Virgine
authors.initials: V
authors.lastname: Lespinet
authors.forename: Mireille
authors.initials: M
authors.lastname: Mari
authors.forename: Sandra
authors.initials: S
authors.lastname: Lassalle
authors.forename: Catherine
authors.initials: C
authors.lastname: Butori
authors.forename: Céline
authors.initials: C
authors.lastname: Coelle
authors.forename: Olivier
authors.initials: O
authors.lastname: Bordone
authors.forename: Eric
authors.initials: E
authors.lastname: Selva
authors.forename: Aude
authors.initials: A
authors.lastname: Lamy
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Sabourin
authors.forename: Paul
authors.initials: P
authors.lastname: Hofman
mesh_terms: D016477:Artifacts; D018070:Biological Specimen Banks; D014408:Biomarkers, Tumor / Q000032:analysis; D035843:Biomedical Research / Q000379:methods; D002458:Cell Fractionation / Q000379:methods; D015510:Clinical Medicine / Q000379:methods; D015925:Cryopreservation / Q000379:methods; D003951:Diagnostic Errors / Q000517:prevention & control; D005260:Female; D005404:Fixatives / Q000494:pharmacology / Q000633:toxicity; D005557:Formaldehyde / Q000494:pharmacology / Q000633:toxicity; D016591:Histocytological Preparation Techniques / Q000379:methods* / Q000592:standards; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000473:pathology*; D009696:Nucleic Acids / Q000302:isolation & purification; D010338:Pathology, Clinical / Q000379:methods* / Q000592:standards; D057089:Pathology, Molecular / Q000379:methods* / Q000592:standards; D011309:Preservation, Biological / Q000379:methods; D015203:Reproducibility of Results; D013048:Specimen Handling / Q000379:methods* / Q000592:standards; D016707:Tissue Fixation / Q000379:methods
chemical_list: D014408:Biomarkers, Tumor; D005404:Fixatives; D009696:Nucleic Acids; D005557:Formaldehyde